Rosiglitazone acts as an agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver
Activation of PPAR-gamma receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, rosiglitazone enhances tissue sensitivity to insulin
The recommended dose range is 4 to 8 mg once or twice daily
Congestive heart failure
Caution should be exercised in patients with history of liver impairment, diabetic ketoacidosis, stroke, heart problems, diabetic eye diseases, anemia, fluid retention, high blood pressure, high cholesterol, who are taking other medications, any allergy, elderly, children, during pregnancy and breastfeeding.
It may cause dizziness, do not drive a car or operate machinery while taking this medication.
Follow diet and exercise program regularly as directed by your physician.
Avoid pregnancy during the treatment period.
Women may develop with increased risk of bone fracture with the following symptoms: unusual bone pain, especially in the hand, foot, or upper arm. If it is so consult with your doctor immediately.
Monitor complete blood cell counts, fasting blood sugar, hemoglobin A1c, eye examinations, and liver function regularly while taking this medication